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Abstract
Background:  Development of hip adductor, tensor fascia lata, and rectus femoris muscle
contractures following total hip arthroplasties are quite common, with some patients failing to
improve despite treatment with a variety of non-operative modalities. The purpose of the present
study was to describe the use of and patient outcomes of botulinum toxin injections as an
adjunctive treatment for muscle tightness following total hip arthroplasty.
Methods:  Ten patients (14 hips) who had hip adductor, abductor, and/or flexor muscle
contractures following total arthroplasty and had been refractory to physical therapeutic efforts
were treated with injection of botulinum toxin A. Eight limbs received injections into the adductor
muscle, 8 limbs received injections into the tensor fascia lata muscle, and 2 limbs received injection
into the rectus femoris muscle, followed by intensive physical therapy for 6 weeks.
Results: At a mean final follow-up of 20 months, all 14 hips had increased range in the affected arc
of motion, with a mean improvement of 23 degrees (range, 10 to 45 degrees). Additionally all hips
had an improvement in hip scores, with a significant increase in mean score from 74 points (range,
57 to 91 points) prior to injection to a mean of 96 points (range, 93 to 98) at final follow-up. There
were no serious treatment-related adverse events.
Conclusion: Botulinum toxin A injections combined with intensive physical therapy may be
considered as a potential treatment modality, especially in difficult cases of muscle tightness that
are refractory to standard therapy.
Background
Adductor and tensor fascia lata muscle contractures fol-
lowing total hip arthroplasty are problems that can com-
promise results. Although certain underlying
neuromuscular conditions such as Parkinson's disease
may increase the risk of post-operative muscle tightness
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[1], the reason for contracture development is unclear in
many patients. There have been recent attempts using var-
ious surgical techniques, including modified and mini-
mally invasive approaches aimed at reducing this
complication. In addition, various rehabilitation algo-
rithms have been utilized in combination with these sur-
gical techniques to attempt to further reduce the incidence
and severity of these functional contractures [2-4].
Despite the reduction in their overall frequency, persistent
contractures remain difficult to treat in some patients and
may require further operative intervention. Some of the
common surgical treatment modalities include adductor
muscle lengthening, tensor fascia lata muscle release,
exploration and resection of adhesions, and revision
arthroplasty [2,5]. These invasive therapeutic techniques
have led to variable outcomes and sometimes only mar-
ginal improvements, with reported success in only 0 to
60% of patients [2,6]. These results suggest that secondary
surgeries are often not beneficial for patients who fail
standard physical therapy interventions, and additional
non-operative treatments should be considered.
There is no consensus concerning the best rehabilitation
or physical therapy methods to treat patients with severe
cases of muscle tightness. After the first indications of stiff-
ness following surgery, mobilization and physical therapy
are generally the first steps taken for treatment of muscle
contractures. However, there are discrepancies in the
reports about the efficacy of various rehabilitation algo-
rithms. When conventional rehabilitation interventions
are unsuccessful, more intensive measures such as manual
therapy, lidocaine injections, bracing, and manipulation
under anesthesia may be employed [2,7]. However, these
methods may fail and other non-operative treatment
options should be considered.
The use of botulinum neurotoxin has been reported for
the treatment of spastic neuromuscular conditions such as
cerebral palsy and idiopathic clubfoot [8-11]. The under-
lying mechanism of action of botulinum toxin occurs at
the cellular level, with neuromuscular transmissions
blocked as a result of the inhibition of acetylcholine
release. By acting selectively on peripheral cholinergic
nerve endings, injected botulinum toxin leads to chem-
odenervation and local paralysis [12]. This temporary
paralysis relieves muscle over-activity, which has been
shown to be a direct cause of muscle shortening and the
associated limitations in both active and passive range of
motion [13]. Furthermore, by alleviating muscle over-
activity, the botulinum injections also ease extrinsic
stretching of the muscle, thus facilitating subsequent ther-
apeutic stretching modalities [14]. The direct clinical
effects of temporary paralysis by botulinum toxin in
humans have been shown to take affect within a few days
and are most effective in the first ten to twelve weeks fol-
lowing treatment [10,15,16]. Based on its ability to block
neuromuscular transmissions, and to provide safe and
temporary muscle paralysis, botulinum toxin type A was
selected as a potential ancillary therapeutic intervention
for this study.
The purpose of this study was to describe the use and the
patient outcomes of botulinum toxin injections in con-
junction with intensive manual joint mobilizations and
stretching programs to treat patients with persistent con-
tractures who were recalcitrant to traditional rehabilita-
tion efforts following total hip arthroplasty.
Methods
The current study encompassed a retrospective review of
ten patients (fourteen hips) who received a total hip
arthroplasty and had post-operative adductor, tensor fas-
cia lata, and/or rectus femoris muscle contractures. The
primary endpoints for this study were an improvement in
hip range of motion and functional outcome. The index
surgeries were performed between March 2002 and Janu-
ary 2008. The greater majority of total hip arthroplasty
patients begin to gain range of motion within 2 to 3 weeks
following their index arthroplasty, and continue to
improve for up to one year. However, in this study, we
specifically addressed a small group of patients who had a
markedly different post-operative course. These patients
showed a distinct pattern of early post-operative muscle
tightness, spasm, and pain, and despite their participating
in therapy for up to 2 months following the index arthro-
plasty, showed no change in range of motion with diffi-
culties participating in rehabilitation efforts. All of these
individuals had persistent post-operative muscle contrac-
tures, and had no concomitant neuromuscular disease.
For this reason, alternative treatments were considered
following 2 months of physical therapy. After meeting
various exclusion and inclusion criteria, these patients
were selected to receive botulinum toxin type A (BoNT/A)
treatment, followed by a 6 week physical therapy regimen.
Patients were seen daily in physical therapy for 2 weeks
following BoNT/A injection, followed by visits 3 times
weekly for an additional 4 weeks. Institutional review
board approval was obtained for this study. All clinical
data collected following botulinum therapy was reviewed
and analyzed for this investigation.
Patient Selection
The inclusion and exclusion criteria used to select total
hip arthroplasty patients for botulinum treatment were:
A) The patient underwent conventional rehabilitation fol-
lowing their joint replacement surgery; B) The initial reha-
bilitation outcome was unsuccessful based on having a
refractory hip flexion and/or abduction contracture of 10
degrees or more, or an inability to abduct the hip past 10
degrees; C) Adductor and tensor fascia lata muscle con-Journal of Orthopaedic Surgery and Research 2009, 4:34 http://www.josr-online.com/content/4/1/34
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tractures were diagnosed based on the individual's com-
plaint of tightness and/or spasms and subsequent clinical
evaluation. The clinical tests included assessment of mus-
cle flexibility using the Thomas test for hip flexors [17,18],
a modified Ober Test [19] for tightness of the tensor fascia
lata and the iliotibial band, and an assessment of hip
abduction range of motion for adductor muscle tightness;
D) The patient had no existing clinical or radiographic
abnormalities such as aseptic or septic loosening, mala-
ligned components, instability, and/or osteolysis. Stand-
ard radiographic examinations and clinical evaluations
were used to identify individuals with one or more of
these exclusion criteria; and E) The patient had no under-
lying symptomatic spastic neuromuscular disease.
There were two men and eight women who met the estab-
lished selection criteria. Nine patients had a primary total
hip arthroplasty and one patient had contractures follow-
ing a revision from a bipolar to a total hip arthroplasty.
The patients had a mean age of 48 years (range, 19 to 66
years). The underlying diagnosis for the total hip arthro-
plasty was osteonecrosis in two hips, and osteoarthritis in
all remaining cases. Twelve hips were treated with metal-
on-metal total hip resurfacing arthroplasty, two hips with
stemmed prostheses and a 22 mm head, and the remain-
ing two hips with a stemmed prosthesis and a 26 mm
head. After surgery, all patients received standard physical
therapeutic modalities at a frequency of 3 times a week.
These modalities included range of motion and progres-
sive resisted strengthening exercises and deep heat treat-
ments. The patients showed minimal improvement in
both functionality and pain following two or more
months of conventional management (except for one at 5
weeks). Common symptoms included: groin pain, back
pain, difficulty walking long distances, and limps.
Patients also complained of difficulty sitting in, and rising
from a chair, as well as descending and ascending stairs.
Radiographs revealed well-aligned components with no
evidence of loosening and no heterotopic ossification in
all patients. Clinical evaluation suggested adductor, rectus
femoris, and/or tensor fascia lata muscle rigidity as the
primary cause of the patients' symptoms. Based on these
findings and the continued poor response to standard
rehabilitation techniques, these patients were qualified
for inclusion in this study.
Botulinum Toxin Type A Treatment
The botulinum toxin type A (BoNT/A) used for treatment
in the present study was supplied in vials of 100 units, sus-
pended in 1 milliliter of solution including 0.5 milligrams
of human albumin and 0.9 milligrams of sodium chloride
(Allergan, Irvine, California). This was further diluted in 4
milliliters of normal saline immediately prior to injection.
The mean time from index surgery to treatment with bot-
ulinum toxin type A injections was 11 months (range, 1 to
69 months). One patient underwent botulinum toxin
treatment five weeks following the index surgery because
it was believed that her progress was sufficiently poor that
further standard rehabilitation would be of limited bene-
fit. All the remaining patients underwent a minimum of 2
full months of standard rehabilitation following the index
arthroplasty. The adductor magnus and brevis muscles
were injected in eight limbs, the tensor fascia lata muscle
in eight limbs, and the rectus femoris muscle was injected
in two limbs. Two patients received injections in both
adductor and tensor fasica lata muscles, and two patients
received injections in both the tensor fascia lata and rectus
femoris muscles. All injections were administered by the
senior author (MAM). Patients were placed in a frog leg
position for the adductor muscle injection, in a lateral
position for the injection of the tensor fascia lata muscle,
and in a supine position for injection of the rectus femoris
muscle. The injections were performed using a 23 or a 25
gauge needle. The injection sites were identified using a
muscle palpation technique, which has previously been
described as adequate for the injection of large, superficial
muscles [20]. For the adductor magnus and brevis mus-
cles, patients were given dosages of 100 units of botuli-
num toxin type A at four sites. Similarly, the rectus femoris
muscles were injected at four sites with a total of 100 units
of BoNT/A, and the tensor fascia lata muscles were
injected at four sites with 100 units of BoNT/A (see Figure
1). These dosages were selected based on previously pub-
lished recommendations for the injection of large muscles
[21].
Immediately following the injections, patients were exam-
ined for any signs of adverse reaction to the toxin (skin
redness, swelling, or systemic symptoms). The patients
were also contacted by telephone one and two days fol-
lowing the injections, and evaluated during subsequent
clinical visits, to ensure that there were no complications
or negative effects due to the toxin. The patients were fol-
lowed for a median of 17 months (mean 20 months;
range, 12 to 62 months) after receiving botulinum ther-
apy.
After receiving the injections, the patients were started on
a rehabilitation regime which consisted of outpatient
treatment for six continuous weeks. Intensive physical
therapy combined with mobilization and stretching of the
adductor and abductor muscles was utilized daily for 2
weeks, followed by three times a week for four weeks. All
patients received targeted muscle stretching and joint
mobilization (Grade III), consisting of holding the joint
at the end of their range for 30 seconds, followed by man-
ual application of 15 to 20 oscillations at the end range of
motion. All of the manual therapy was performed with
opposite limb immobilization and pelvic stabilization.
We used modified Ober or Kendall positioning for mobi-Journal of Orthopaedic Surgery and Research 2009, 4:34 http://www.josr-online.com/content/4/1/34
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lization of the tensor fascia lata muscle. The rectus femoris
muscle was mobilized in the Ely position, and the adduc-
tor muscles were stretched in both frog leg and supine
positions. Each mobilization was performed for 30 to 45
seconds with end-range oscillations. Typically, patients
were treated with 7 to 10 mobilizations for each move-
ment pattern. In addition, all patients received hip flexor
mobilization in the Thomas test position. All patients
received a standard home exercise program prescribed to
all hip arthroplasty patients at our institution for contin-
ued joint mobilization and muscle strength maintenance
following the completion of formal physical therapy.
Only patients with a minimum of 12 months follow-up
were included in this report. In the absence of any specific
complaints, follow-up intervals after 12 months were on
an annual basis as per our institution's standard total hip
arthroplasty follow-up guidelines.
Prior to index surgery and throughout follow-up, contrac-
ture and arc of motion measurements were made for each
subject using a bubble goniometer to assess the clinical
outcome. Patients were also evaluated using the Harris
hip score rating system [22].
Statistical Analysis
Data was subjected to averaging and analysis using Sigma
Stat software (version 3.00, Systat Corporation, San Jose,
California). The clinical outcomes following botulinum
toxin type A injection were compared to those prior to
treatment using a paired t test, where a p-value of < 0.05
was considered significant.
Results
All 14 hips achieved a minimum of 10 degrees improve-
ment of arc of motion previously restricted by the con-
tracted muscles, with an overall mean improvement in arc
of motion of 23 degrees (range, 10 to 45 degrees).
The eight hips with adductor muscle contractures had a
mean improvement in maximum abduction of 31 degrees
(range, 20 to 45 degrees), from a pre-injection mean max-
imal abduction of 8 degrees (range, -5 to 15 degrees) to 38
degrees (range, 15 to 55 degrees) at final follow-up. The
eight hips that had tensor fascia lata contractures had a
mean improvement in maximum adduction of 16 degrees
(range, 10 to 25 degrees), from a pre-injection mean max-
imal adduction of -9 degrees (range, -15 to -5 degrees) to
a mean of 7 degrees (range, -5 to 20 degrees) at final fol-
low-up. Both hips with flexion contractures achieved full
extension, with a mean decrease in fixed flexion deformity
of 15 degrees (range, 10 to 20 degrees). A comprehensive
overview of the results for all treated patients can be found
in Additional File 1.
All of the treated hips had Harris hip scores of 80 points
or more at the time of final follow-up, and were consid-
ered to have a successful clinical outcome. The mean
improvement in Harris Hip scores from the time of injec-
tion to final follow-up was 22 points (range, 2 to 40
points). The Harris Hip scores improved from a mean of
53 points (range 25 to 75 points) prior to index surgery,
to a mean of 74 points (range 57 to 91 points) prior to
botulinum toxin injection, and to a mean of 96 points
(range 93 to 98 points) at final follow-up (p < 0.001; see
Table 1).
There were no serious complications directly associated
with the botulinum treatment. Two patients developed
mild, transient flu-like symptoms that lasted for two days.
However, the patients recovered without further difficul-
ties and showed no noted later effects. Three patients
developed redness and swelling at the injection site last-
ing for several days following treatment, but which
resolved within one week in all cases.
Discussion
There is still controversy concerning the preferred treat-
ment algorithm for muscle contractures following total
hip arthroplasty. As previously described, the results of
physical therapy have been less than optimal in some dif-
ficult cases, and regardless of the specific protocol, there
remain a number of cases that do not respond to standard
non-operative treatment methods. The present study
identified a cohort of patients who continued to show
Botulinum toxin injection points Figure 1
Botulinum toxin injection points. Illustration of the loca-
tions of the botulinum toxin injections into the adductor, 
tensor fascia lata, and rectus femoris muscles.Journal of Orthopaedic Surgery and Research 2009, 4:34 http://www.josr-online.com/content/4/1/34
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post-operative muscle contractures and unsatisfactory
clinical outcomes despite aggressive rehabilitation efforts.
This difficult-to-treat patient group was selected to evalu-
ate the effectiveness of using BoNT/A injections as a new
ancillary treatment modality in the most severe cases of
flexion contracture.
Until recently, there have been few studies indicating that
utilized botulinum toxin injections in orthopaedic
patients [21,23]. In a study by Alvarez et al., it was used to
manage limb spasticity in fifty-one patients with idio-
pathic clubfoot [8]. None of the patients had prior surgery
for clubfoot, and the botulinum toxin was utilized as a
substitute for tenotomy to attenuate the function of the
triceps surae muscle complex. The patients were followed
for a mean of 15 months (range, 1 to 27 months). The
results were given for two groups: the first group included
patients less than one month old (29 patients), and the
second group comprised individuals who were more than
one month of age (22 patients). One month following
botulinum toxin treatment, the mean ankle dorsiflexion
with the knee in flexion improved from 8.0 ± 11.6 degrees
to 31.5 ± 11.8 degrees in the first group and 6.1 ± 9.7
degrees to 24.6 ± 9.7 degrees in the second group. The
ankle dorsiflexion in flexion remained above 20 degrees
for both groups at final follow-up. Similarly, the mean
dorsiflexion in extension also improved for both groups,
remaining above 15 degrees at a final follow-up of 9
months (range, 1 week to 27 months). Overall, only one
patient required limited posterior release and nine
patients required repeat manipulation and casting. Based
on these results, the study identified botulinum type A as
an effective therapeutic approach for idiopathic clubfoot.
To the best of our knowledge, there are only four reports
in the literature that evaluated the use of BoNT/A treat-
ment following lower extremity joint arthroplasty. Seyler
et al. reported on preliminary results of 11 knee flexion
contractures after total knee arthroplasties [24]. Overall, 9
of the 11 knees achieved extension to within 10 degrees of
neutral by 2 years following BoNT/A treatment, and 8 of
11 knees maintained this result at a mean follow-up of 36
months. Fish and Chang reported a case of treating iliop-
soas tendinitis after a left total hip arthroplasty [25]. The
71 year old woman reported pain that had worsened over
a 4 month period and had been made worse by daily
activities such as walking and climbing stairs. She showed
no signs of periprosthetic infection or malpositioning of
the prosthesis. Following injection of 100 units of BoNT/
A, both her function and pain showed improvements by
6 months. Her Oswestry Disability index decreased from
26 to 18 points, and her pain intensity numerical rating
scale decreased from 7 to 1 on a 10-point scale. The
authors suggested that this technique may be an alterna-
tive to surgical intervention. Bertoni at al reported the case
of a female patient who suffered from complications after
total hip arthroplasty [26]. Due to severe pain in the glu-
teal region not responding to standard treatments, the
patient was unable to stand in an upright position or
walk, and she was forced to stop her rehabilitation pro-
gram. Treatment by injection of BoNT/A in the gluteus
maximus muscle brought about complete resolution of
pain and functional recovery. At final follow up of 16
months, hip assessment confirmed complete pain reduc-
tion. Shah et al. reported on the use of botulinum injec-
tions for the treatment of a flexion contracture following
a total knee arthroplasty in a 61 year old patient with Par-
kinson's disease [27]. Despite physical therapy, the
patient showed little improvement and range of motion
was only from 30 to 100 degrees of flexion at one month
follow-up. At six weeks after surgery, the patient was
injected with 200 units of botulinum toxin type A in the
long head of the biceps femoris and the semitendinosus
muscle, and at four months he was injected in the gastroc-
nemius muscle. At final follow-up of 6.5 months, the
patient's range of motion improved to 8 to 125 degrees.
Some authors have expressed concerns regarding the cost
of using botulinum type A injections to treat muscle
spasms [28]. This concern is relevant for patients who suf-
fer from neurological conditions that cause chronic mus-
cle spasms as they would likely require continuous,
periodic botulinum treatments. However, none of the
patients in this study had flexion contractures associated
with a neurological disorder and would ideally require
only one treatment. While the authors await long-term
results to see if the initial botulinum treatment is suffi-
cient, the mean follow-up of 20 months for this study sug-
gests that a single dose botulinum injection can provide
desirable results beyond the ten to twelve weeks in which
botulinum is most effective as a neuromuscular transmis-
sion inhibitor. No formal physical therapy was required
beyond six weeks to maintain these results.
BoNT/A injections may be used with or without local
anesthetic, and the toxin has no affect on sensation fol-
lowing treatment. Reports of complications such as fever,
pain, local irritation, and redness following BoNT/A bot-
ulinum injections are rare, and the effects have only been
Table 1: Comparison of mean Harris hip scores prior to surgery, 
prior to botulinum toxin injection, and at final follow-up
points p value
Mean pre-operative Harris hip score 53
<0.001
Mean pre-injection Harris hip score 74
<0.001
Mean final follow-up Harris hip score 96
p values were calculated using a paired t-testJournal of Orthopaedic Surgery and Research 2009, 4:34 http://www.josr-online.com/content/4/1/34
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temporary. While reactions to the injections were not
uncommon in our study group, the effects were relatively
minor, of short duration, and resolved without any fur-
ther problems, which was consistent with the low risk
level associated with the use of BoNT/A injections.
The limitations of this study include the relatively short-
term follow-up, the small numbers of hips (n = 14), and
the possible patient selection bias. In addition, this is a
retrospective case series with no comparison group, mak-
ing it impossible to determine whether these patients
might have experienced some functional improvement
without this treatment method. Although a review of the
records did not reveal any sizeable pre-operative muscle
contractures, the design of the study did not allow for an
accurate assessment of the duration of the pre-operative
disability, which might have influenced the post-opera-
tive course. Nevertheless, despite these limitations, we did
find significant clinical improvement and good outcomes,
without severe complications in this difficult to treat
group of patients who had not made progress. Although
only a preliminary study, we believe that these results pro-
vide useful information to the orthopaedic community
regarding the treatment of patients with muscle tightness
after total hip arthroplasty who are refractory to standard
rehabilitation protocols. We are presently studying this
treatment modality in a prospective and controlled man-
ner.
Conclusion
These therapeutic findings suggest that the ancillary use of
BoNT/A injections when combined with physical thera-
peutic modalities improved clinical results for patients
with hip adductor and tensor fascia lata muscle tightness
who do not respond to conventional treatment modali-
ties. The clinical significance of this study is that patients
with contractures who are severely debilitated can have an
improved quality of life after BoNT/A, reflected by
increased functional abilities and/or decreased pain.
Additional studies with larger patient cohorts are cur-
rently underway, and the authors await long-term results
to see if the promising results of this study can be main-
tained.
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